{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxane+Compound&page=4", "query": { "intervention": "Taxane Compound", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 281, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxane+Compound&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxane+Compound&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:31:34.397Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01491737", "title": "A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Induction Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 258, "start_date": "2012-02-17", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01491737" }, { "nct_id": "NCT00044538", "title": "Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "BAY59-8862 (Cytotoxic Taxane)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2001-12", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2009-06-22", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 7, "location_summary": "Tucson, Arizona • Waterbury, Connecticut • Louisville, Kentucky + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044538" }, { "nct_id": "NCT00082433", "title": "Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer", "Breast Cancer" ], "interventions": [ { "name": "Ixabepilone + Capecitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1221, "start_date": "2003-11", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2020-11-02", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 34, "location_summary": "Tucson, Arizona • Beverly Hills, California • Corona, California + 31 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082433" }, { "nct_id": "NCT02391818", "title": "The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Distorted; Balance", "Quality of Life", "Neuropathy", "Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "OSF Healthcare System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 19, "start_date": "2015-02", "completion_date": "2017-06-16", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 4, "location_summary": "Pekin, Illinois • Peoria, Illinois", "locations": [ { "city": "Pekin", "state": "Illinois" }, { "city": "Pekin", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02391818" }, { "nct_id": "NCT07578116", "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic HER2-Positive Breast Carcinoma", "Oligometastatic Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Breast Conservation Treatment", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclin-Dependent Kinase 4 Inhibitor", "type": "DRUG" }, { "name": "Cyclin-Dependent Kinase 6 Inhibitor", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "HER2-targeted Therapy", "type": "DRUG" }, { "name": "Hormone Therapy", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Boost", "type": "RADIATION" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Taxane Compound", "type": "DRUG" }, { "name": "Total Mastectomy", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 562, "start_date": "2027-03-09", "completion_date": "2033-05-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 59, "location_summary": "Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Greenwich", "state": "Connecticut" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07578116" }, { "nct_id": "NCT07864792", "title": "Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who Received Taxene and/or Platinum Chemotherapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Sham Intervention", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Transcranial Direct Current Stimulation", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DEVICE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "85 Years", "sex": "FEMALE", "summary": "60 Years to 85 Years · Female only" }, "enrollment_count": 60, "start_date": "2026-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07864792" }, { "nct_id": "NCT01221870", "title": "Tesetaxel as First-line Therapy for Metastatic Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasm" ], "interventions": [ { "name": "Tesetaxel once every 3 weeks", "type": "DRUG" }, { "name": "Tesetaxel once weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genta Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2010-11", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2012-07-24", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 4, "location_summary": "New York, New York • Greensboro, North Carolina • Memphis, Tennessee + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Greensboro", "state": "North Carolina" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221870" }, { "nct_id": "NCT05107674", "title": "A Study of NX-1607 in Adults With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "NX-1607", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2021-09-29", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107674" }, { "nct_id": "NCT01050075", "title": "Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Stage I Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "acupuncture therapy", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "management of therapy complications", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2010-01", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01050075" }, { "nct_id": "NCT05259527", "title": "Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuropathic Pain" ], "interventions": [ { "name": "Ergocalciferol Capsules", "type": "DRUG" }, { "name": "Cholecalciferol Capsules", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2022-12-19", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-13T23:31:34.397Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259527" } ] }